Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

View ORCID ProfileAriel Israel, Yotam Shenhar, Ilan Green, View ORCID ProfileEugene Merzon, Avivit Golan-Cohen, View ORCID ProfileAlejandro A Schäffer, View ORCID ProfileEytan Ruppin, View ORCID ProfileShlomo Vinker, View ORCID ProfileEli Magen
doi: https://doi.org/10.1101/2021.08.19.21262111
Ariel Israel
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ariel Israel
  • For correspondence: dr.ariel.israel@gmail.com
Yotam Shenhar
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ilan Green
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene Merzon
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eugene Merzon
Avivit Golan-Cohen
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro A Schäffer
3Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alejandro A Schäffer
Eytan Ruppin
3Cancer Data Science Laboratory, National Cancer Institute, Bethesda, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eytan Ruppin
Shlomo Vinker
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
2Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shlomo Vinker
Eli Magen
1Leumit Research Institute & Department of Family Medicine, Leumit Health Services, Israel
4Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben Gurion University of the Negev, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eli Magen
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Immune protection following either vaccination or infection with SARS-CoV-2 decreases over time.

Objective To determine the kinetics of SARS-CoV-2 IgG antibodies following administration of two doses of BNT162b2 vaccine, or SARS-CoV-2 infection in unvaccinated individuals.

Methods Antibody titers were measured between January 31, 2021, and July 31, 2021 in two mutually exclusive groups: i) vaccinated individuals who received two doses of BNT162b2 vaccine and had no history of previous infection with COVID-19 and ii) SARS-CoV-2 convalescents who had not received the vaccine.

Results A total of 2,653 individuals fully vaccinated by two doses of vaccine during the study period and 4,361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated individuals (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination, than in convalescent individuals (median 355.3 AU/mL IQR [141.2-998.7]; p<0.001). In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month. Six months after BNT162b2 vaccination 16.1% subjects had antibody levels below the seropositivity threshold of <50 AU/mL, while only 10.8% of convalescent patients were below <50 AU/mL threshold after 9 months from SARS-CoV-2 infection.

Conclusions This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.

Funding This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Impact statement Large scale study display the kinetics of SARS-CoV-2 IgG antibodies present in individuals vaccinated with two doses of mRNA vaccine vs. unvaccinated patients who had recovered from the disease: initial levels of antibody are much higher in vaccinated patients, but decrease faster.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was internally funded by Leumit Health Services (LHS) and was supported in part by the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was approved by Shamir Medical Center Institutional Review Board (129-2-LEU).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • (e-mail: dr.ariel.israel{at}gmail.com), (e-mail: yshenhar{at}leumit.co.il), (e-mail: igreen{at}leumit.co.il), (e-mail: emarzon{at}leumit.co.il), (e-mail: agolanchoen{at}leumit.co.il), (e-mail: alejandro.schaffer{at}nih.gov), (e-mail: eytan.ruppin{at}nih.gov), (e-mail: svinker{at}leumit.co.il), (e-mail: allergologycom{at}gmail.com)

  • Conflict of Interest disclosure statement: All authors have no conflicts to disclose

Data Availability

Data were obtained from patients' electronic health records, and IRB approval restrains its use to researchers inside Leumit Health Services.

  • Abbreviations

    COVID-19
    Coronavirus disease of 2019
    SARS-CoV-2
    Severe acute respiratory syndrome coronavirus 2
    mRNA
    Messenger RNA
    LHS
    Leumit Health Services
    HMO
    Health maintenance organization
    SES
    Socio-economic status
    BMI
    Body mass Index
    IQR
    Interquartile range
    RT-PCR
    Reverse transcription polymerase chain reaction
    IgG
    Immunoglobulin G
    BMPCs
    Bone marrow plasma cells
    ACE2
    Angiotensin-converting enzyme 2
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted August 22, 2021.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
    Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen
    medRxiv 2021.08.19.21262111; doi: https://doi.org/10.1101/2021.08.19.21262111
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection
    Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen
    medRxiv 2021.08.19.21262111; doi: https://doi.org/10.1101/2021.08.19.21262111

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (214)
    • Allergy and Immunology (495)
    • Anesthesia (106)
    • Cardiovascular Medicine (1091)
    • Dentistry and Oral Medicine (194)
    • Dermatology (141)
    • Emergency Medicine (274)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
    • Epidemiology (9747)
    • Forensic Medicine (5)
    • Gastroenterology (480)
    • Genetic and Genomic Medicine (2298)
    • Geriatric Medicine (221)
    • Health Economics (461)
    • Health Informatics (1548)
    • Health Policy (729)
    • Health Systems and Quality Improvement (600)
    • Hematology (236)
    • HIV/AIDS (500)
    • Infectious Diseases (except HIV/AIDS) (11620)
    • Intensive Care and Critical Care Medicine (615)
    • Medical Education (236)
    • Medical Ethics (67)
    • Nephrology (256)
    • Neurology (2136)
    • Nursing (133)
    • Nutrition (332)
    • Obstetrics and Gynecology (424)
    • Occupational and Environmental Health (516)
    • Oncology (1171)
    • Ophthalmology (363)
    • Orthopedics (128)
    • Otolaryngology (220)
    • Pain Medicine (145)
    • Palliative Medicine (50)
    • Pathology (308)
    • Pediatrics (692)
    • Pharmacology and Therapeutics (298)
    • Primary Care Research (265)
    • Psychiatry and Clinical Psychology (2168)
    • Public and Global Health (4640)
    • Radiology and Imaging (775)
    • Rehabilitation Medicine and Physical Therapy (450)
    • Respiratory Medicine (622)
    • Rheumatology (273)
    • Sexual and Reproductive Health (224)
    • Sports Medicine (208)
    • Surgery (250)
    • Toxicology (42)
    • Transplantation (120)
    • Urology (94)